Aptevo Therapeutics Inc (NASDAQ:APVO) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $2.22 and last traded at $2.26, with a volume of 95468 shares changing hands. The stock had previously closed at $2.41.

Several brokerages have recently issued reports on APVO. Zacks Investment Research upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a report on Tuesday, August 14th. Piper Jaffray Companies restated an “overweight” rating and issued a $11.00 target price on shares of Aptevo Therapeutics in a report on Friday, August 10th. ValuEngine upgraded shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, August 13th. LADENBURG THALM/SH SH began coverage on shares of Aptevo Therapeutics in a report on Monday, November 5th. They issued a “buy” rating and a $14.00 target price for the company. Finally, Roth Capital set a $12.00 target price on shares of Aptevo Therapeutics and gave the company a “buy” rating in a report on Thursday, November 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $10.69.

The company has a current ratio of 3.91, a quick ratio of 3.65 and a debt-to-equity ratio of 0.43. The firm has a market cap of $54.68 million, a PE ratio of -1.47 and a beta of 2.06.

Aptevo Therapeutics (NASDAQ:APVO) last issued its earnings results on Wednesday, November 14th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.01. Aptevo Therapeutics had a negative net margin of 252.44% and a negative return on equity of 78.85%. The business had revenue of $5.82 million during the quarter, compared to analysts’ expectations of $6.87 million. Research analysts forecast that Aptevo Therapeutics Inc will post -2.31 earnings per share for the current year.

Several institutional investors have recently modified their holdings of APVO. Dimensional Fund Advisors LP raised its position in Aptevo Therapeutics by 5.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,425,567 shares of the biotechnology company’s stock valued at $7,242,000 after purchasing an additional 73,911 shares during the last quarter. Renaissance Technologies LLC raised its position in Aptevo Therapeutics by 11.1% in the 3rd quarter. Renaissance Technologies LLC now owns 1,277,100 shares of the biotechnology company’s stock valued at $6,488,000 after purchasing an additional 127,700 shares during the last quarter. Sessa Capital IM L.P. raised its position in Aptevo Therapeutics by 35.9% in the 3rd quarter. Sessa Capital IM L.P. now owns 706,613 shares of the biotechnology company’s stock valued at $3,590,000 after purchasing an additional 186,719 shares during the last quarter. Acadian Asset Management LLC raised its position in Aptevo Therapeutics by 20.2% in the 3rd quarter. Acadian Asset Management LLC now owns 441,765 shares of the biotechnology company’s stock valued at $2,244,000 after purchasing an additional 74,256 shares during the last quarter. Finally, EAM Investors LLC purchased a new stake in Aptevo Therapeutics in the 2nd quarter valued at $552,000. Institutional investors and hedge funds own 32.77% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/aptevo-therapeutics-apvo-hits-new-1-year-low-at-2-22/2667566.html.

Aptevo Therapeutics Company Profile (NASDAQ:APVO)

Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.

See Also: Preferred Stock

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.